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Abstract Dark adaptometry may be a useful diagnostic test
and clinical trial endpoint for age-related maculopathy
(ARM) because impaired night vision is a hallmark of
early ARM. A novel dark adaptometer, the AdaptDx, was
evaluated for the detection of ARM. The AdaptDx
incorporates a 20-minute protocol optimized for the
detection of ARM. ARM patients (N=17) exhibited
substantial dark adaptation impairment compared with
normal adults (N=17). The diagnostic sensitivity was 88%
and the specificity was 100%. The diagnostic test character-
istics of the AdaptDx are similar to previously reported
studies using 60- to 120-minute protocols.
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Introduction
Age-related maculopathy (ARM), also known as age-
related macular degeneration, affects approximately 30
million people worldwide. In the United States, there are
an estimated 13 million people with some vision loss from
ARM, including two million with the most severe late-stage
of the disease. Fortunately, there are an increasing number
of effective treatments for late-stage disease, such as
pegaptabnib (Macugen; Pfizer) and ranibizumab (Lucentis;
Genetech). However, treatment of advanced ARM often
results in less than optimal patient outcomes because
moderate to severe irreversible vision loss has already
occurred before stabilization. The treatment of the disease
in its earliest stages is the best strategy to preserve the
patient’s vision, which may be only mildly disturbed as
measured by high contrast visual acuity measured under
high luminance conditions.
There are significant barriers to the development of treat-
mentsforearlyARM.The disease’sslowprogressionhampers
the feasibility of clinical trials because currently accepted
endpoints of acuity and fundus appearance are relatively
insensitive to the disease’s progression through its earliest
stages. These endpoints require clinical trials to have large
samplesizesorlongfollow-updurationstoevaluateefficacyof
a potential treatment. Clinical trials evaluating early treatments
are impractical because of the constraints current endpoints
impose on trial design. More sensitive endpoints are required
to enhance the feasibility of early ARM clinical trials.
While patients with early ARM typically have good
best-corrected visual acuity, impaired night vision is a
prominent self-reported problem [1–3]. Anatomical studies
of donor eyes have documented significant rod dysfunction
and photoreceptor drop out in comparison to cone photo-
receptors [4]. Histopathological studies have found ARM-
related lesions in the RPE and Bruch’s membrane, which
are generally invisible to clinical inspection [5, 6]. Not
surprisingly, these insults to the photoreceptors and the
RPE, which supports the photoreceptors, disrupt vision.
Early ARM patients exhibit moderate to severe impairment
j ocul biol dis inform (2008) 1:7–11
DOI 10.1007/s12177-008-9002-6
Financial Disclosure: G. Jackson and J. Edwards hold intellectual
property related to the AdaptDx. J. Edwards has a significant financial
interest in the AdaptDx.
G. R. Jackson (*)
Department of Ophthalmology, Penn State College of Medicine,
500 University Drive, HU19,
Hershey, PA 17033-0850, USA
e-mail: gjackson@psu.edu
J. G. Edwards
Apeliotus Technologies, Inc.,
Atlanta, GA, USAof rod-mediated dark adaptation and scotopic visual
sensitivity even in the absence of visual acuity loss [7, 8].
Rod-mediated dark adaptation appears to be more impaired
in early ARM patients than photopic visual sensitivity,
scotopic visual sensitivity, acuity, and contrast sensitivity
[8]. Advanced ARM patients exhibit impaired cone-
mediated dark adaptation [9–12] and early ARM patients
exhibit photostress impairment [13, 14]. However, rod-
mediated dark adaptation appears to be more affected than
cone-mediated dark adaptation at least outside the fovea in
early ARM patients [15]. Rod-mediated dark adaptation
impairment is modestly reversible with vitamin A supple-
mentation, whereas cone-mediated dark adaptation impair-
ment is not [2]. Impairment of rod-mediated dark adaptation
is related to the disease severity [8]. A pilot retrospective
study suggests that the rod-mediated dark adaptation
impairment is detectable at least 4 years before the lesions
associated with the disease are clinically apparent (unpub-
lished data). These findings suggest that dark adaptation
impairment is a sensitive marker of early ARM and raises the
possibility that it may used to predict progression.
The utility of dark adaptometry as a clinical outcome
measure or practical diagnostic tool is hampered by a long
test duration, high participant burden, and lack of standard-
ized dark adaptometers. Dark adaptation protocols used in
prior research require up to 90 minutes, and typically more
than 100 threshold estimates are made. The long duration
and number of thresholds measurements may fatigue some
patients and aversively affect reliability. These limitations
prevent the inclusion of dark adaptometry in clinical trials.
The goal of this study was to develop a short-duration
dark adaptation protocol that minimized patient fatigue,
increased operator ease of use, and maintained the high
sensitivity and specificity of research protocols. The protocol
evaluated in this study has three distinct differences
compared with prior research protocols: (1) the bleaching
light intensity was significantly reduced to shorten the
duration necessary to measure sensitivity recovery; (2) the
stimulus was located within the area of greatest rod
dysfunction to enhance the sensitivity of the test for detection
of early disease; and (3) the speed of dark adaptation was
estimated using a parameter that is robust to the shape of the
dark adaptation function, which can be variable with disease
severity. This protocol was implemented using a new dark
adaptometer, the AdaptDx, developed in collaboration with
Apeliotus Technologies, Inc. (Atlanta, GA). This study
evaluated the sensitivity and specificity of the protocol.
Materials and methods
The Institutional Review Board of the University of
Alabama at Birmingham approved this study. Written
informed consent was obtained from all participants after
the nature and possible consequences of the study were
explained. Normal adults and early to intermediate ARM
patients were recruited from the comprehensive ophthal-
mology and retina services of the Department of Ophthal-
mology, University of Alabama at Birmingham.
Inclusion criteria were as follows: (1) participants were
20 to 45 years old for the young normal group and
participants were at least 55 years of age for the old normal
and ARM groups; and (2) best-corrected distance visual
acuity of 20/100 or better in at least one eye. If both eyes
qualified, the eye with the better acuity was enrolled as the
test eye. If the acuities were the same, the right eye was
enrolled as the test eye.
Exclusion criteria were as follows: (1) medical record or
a general health interview indication of glaucoma, optic
neuropathy or any ocular conditions other than ARM, or
refractive error (spherical equivalent) having an absolute
value >6 diopters; (2) neurological diseases such as
Alzheimer’s disease, Parkinson’s disease, history of stroke
or multiple sclerosis; (3) diabetes; and/or (4) inability to
perform the psychophysical task used to measure dark
adaptation.
Best-corrected distance visual acuity was measured for
each eye using the EDTRS chart and expressed as logMAR.
Dark adaptation was measured using the AdaptDx, a
computer-automated dark adaptometer. Figure 1 shows the
patient’sv i e w .T h ep a t i e n t ’s test eye is dilated to ≥6m m
diameter, and corrective lenses are introduced as appropriate
for the 30-cm viewing distance to correct for blur. The fellow
eye is occluded with an eye patch. An infrared camera
located behind the fixation light continuously monitors the
patient’s test eye and displays an image of the eye on a
personal computer-based operator control screen. The
Fig. 1 The patient’s view of the AdaptDx. The bleaching light (not
shown) is presented through an aperture co-localized with the stimulus
light
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with the help of a reticule displayed on the image of the eye.
The patient’s test eye is bleached by exposure to a photoflash
(0.25 ms duration, 6.38 log scot Td second
−1 intensity) while
the patient is focused on the fixation light. The flash of light
passes through a diffuser and 4°-diameter aperture centered
at 5° on the inferior visual meridian to provide a uniform
focal bleach surrounding the area to be tested during
sensitivity recovery measurements. Sensitivity measurements
begin immediately after bleach offset. The patient focuses on
the fixation light, and responds that a stimulus light is
present by pushing a button. The stimulus light is a 1.7°
circular test spot located at 5° on the inferior visual meridian.
To focus on rod-mediated function, a stimulus wavelength of
500 nm was used, which is near the peak of rod sensitivity.
Sensitivity is estimated using a three-down/one-up modified
staircase threshold estimate procedure. Starting at a relatively
high intensity (5.00 cd/m
2), stimulus lights are presented
every two or three seconds for a 200-ms duration. If the
patient does not respond within 2 seconds of stimulus onset,
the stimulus light intensity remains unchanged on successive
stimulus presentations until the patient responds. If the
patient indicates that the stimulus is visible, the intensity is
decreased for each successive presentation in steps of 0.3 log
units until the patient stops responding that the stimulus is
visible. After the patient indicates that the stimulus light is
invisible by not pressing the button while the stimulus light
is present, the intensity of the target is increased for each
successive presentation in 0.1 log unit steps until the patient
responds that the stimulus light is once again visible. This
intensity is defined as a threshold. Successive threshold
measurements start with the stimulus intensity 0.2 log units
brighter than the previous threshold measurement. The
patient has a 30-second rest period between threshold
measurements. Threshold measurements are made about
once a minute for the duration of the measurement protocol;
thus about 20 threshold measurements are made during the
20-minute test.
Because ARM patients can exhibit several differently
shaped dark adaptation functions, the “rod intercept”,a n
estimate of recovery speed that is robust to shape, was used.
The rod intercept is the amount of time after bleach offset
required for the patient’s sensitivity to recover to a stimulus
intensity of 5×10
−4 cd/m
2 (i.e.; 4.0 log units). This light
level was chosen because it typically is achieved late in the
second component of rod-mediated dark adaptation and is
therefore completely mediated by rod function. Each
subject’s dark adaptation function is plotted and the rod
intercept is estimated by linear interpolation. Patients with
normal rod recovery will have shorter rod intercepts than
those with impaired dark adaptation.
Stereoscopic 30° photographs were taken with a FF450
Plus Zeiss fundus camera for all participants more than 54
years old. Photographs were evaluated using the Age-
related Eye Disease Study (AREDS) Severity Scale for
Age-Related Macular Degeneration [16] by two indepen-
dent graders who were masked to the clinical and functional
characteristics of the participants. Group assignment to
normal or ARM was based on the AREDS severity score of
the test eye. These steps are indicative of normal (step 1),
borderline ARM (our terminology) (step 2), early ARM
(steps 3–6), intermediate ARM (steps 7–9), and advanced
ARM (steps 10 and 11).
Results
The study population consisted of eight normal young adults
(mean age=32.6 years old), nine normal old adults (mean
age=73.1 years old) and 17 ARM patients (mean age=75.1
years old). The old normal and ARM groups had similar
ages (p=0.42) and test eye acuities (p=0.14) (Table 1).
Table 1 Participant demographics
Young Normal (N=8) Old Normal (n=9) ARM (n=17)
Age (years), mean (SD) 32.6 (5.3) 73.1 (4.8) 75.1 (6.4)
Gender, % (n)
Female 100 (8) 66.7 (6) 52.9 (9)
Male 0 (0) 33.3 (3) 47.1 (8)
Race, % (n)
White 62.5 (5) 88.9 (8) 100 (17)
African American 25.0 (2) 11.1 (1) 0 (0)
Asian 12.5 (1) 0 (0) 0 (0)
Visual acuity, logMAR mean (SD)
Tested eye −.02 (0.4) .04 (.12) .14 (.19)
Fellow eye .05 (0.1) .14 (.21) .52 (.40)
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adults than ARM patients (p=0.01). ARM patients exhibited
substantially slower dark adaptation compared with normal
old adults; whereas the dark adaptation speed was essentially
the same for the young and old normal participants.
Representative dark adaptation functions for a young normal
adult, an early ARM patient and an intermediate ARM
patient are shown in Fig. 2. The rod intercept for ARM
patients (mean=17.20 min, SD=3.8) was on average twice
as long as the rod intercept for normal old adults (mean=
8.73 min, SD=1.9) (p<0.0001). Nine of the 17 ARM
patients failed to obtain the criterion sensitivity within the
20-minute protocol, and were assigned a rod intercept of
20 min; thus the substantial difference between these
averages actually understates the relative impairment be-
tween the two groups. The rod intercept for normal young
adults (mean=8.2 min, SD=1.4) was statistically indistin-
guishable from normal old adults (p=0.76).
Each subject’s dark adaptation was classified as normal
or impaired based whether the participant’s speed of dark
adaptation as measured by the rod intercept fell within the
normal reference range (mean ± 2 SD) of the normal old
adults. The upper limit of the normal reference range was
12.5 minutes. Individuals with rod intercepts longer than
12.5 minutes were classified as having impaired dark
adaptation. Participants with a rod intercept ≤12.5 were
classified as having normal dark adaptation. Using this
criterion, 15 of the 17 ARM patients were classified as
having abnormal dark adaptation for a diagnostic sensitivity
of 88%. All nine normal adults fell within the normal
reference range for a diagnostic specificity of 100%. The
sensitivity and specificity of our 20-minute study protocol
compares favorably to that of a previously used 90-minute
research protocol (85% sensitivity; 100% specificity) [8],
despite the considerable shortening of the test. Furthermore,
it is useful to examine the two false negative results (those
ARM patients classified with normal dark adaptation). Both
were for participants with an AREDS fundus grade of 2.
One of these patients exhibited three drusen of 63 μm
scattered throughout the central 3,000 μm of the macula.
The other patient had a small amount of hyperpigmentation
surrounding a single 63-µm druse. The sensitivity of the
test is 100% for those ARM patients with an AREDS grade
3 and higher.
A ss h o w ni nT a b l e2,d a r ka d a p t a t i o ni m p a i r m e n t
increased with ARM severity. Old normal adults had a
mean rod intercept of 8.7 min. The rod intercept for
borderline ARM patients (AREDS fundus grade 2) was, on
average, 5.1 minutes slower than the normal old adult’s rod
intercept. The rod intercept for early ARM patients
(AREDS fundus grades 3 to 5) was, on average, yet
another 3.4 minutes slower than borderline ARM patients.
Finally, all of the intermediate and late ARM patients
(AREDS fundus grades ≥ 6) failed to reach the rod
intercept within the 20-minute test time.
Conclusions
Using a 20-minute, rod-mediated dark adaptation protocol,
ARM patients exhibited a dramatic slowing of dark
adaptation in comparison with normal old adults. The
magnitude of the impairment was similar to that previously
measured using a 90-minute research protocol [8]. As
expected, reducing the bleaching light shortened the
duration of the test, and moving the stimulus to an area of
greater rod dysfunction preserved the sensitivity and
specificity of the protocol. The magnitude of the dark
Table 2 Dark adaptation impairment increased with disease severity
Young Normal Old Normal Borderline ARM Early ARM Intermediate ARM Advanced ARM
Sample Size 8 9 5 6 5 1
AREDS Fundus Grade N/A
a 1 2 3,4,5 6,7,8,9 ≥10
Rod Intercept, min mean (SD) 8.2 (1.4) 8.7 (1.9) 13.8 (4.4) 17.2 (2.7) 20 (
b)2 0 (
b)
aFundus photography and grading was not performed on young normal group.
bAll subjects failed to reach the rod intercept within the 20-minute test duration. Rod intercepts were set at 20 minutes for comparison purposes.
Fig. 2 Representative dark adaptation curves of a normal adult
(closed circles), early ARM patient (open triangles), and intermediate
ARM patient (open circles)
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suggests that a rapid diagnostic screening test having a
duration of less than 10 minutes is feasible. Test–retest
reliability was found to be quite high (intraclass r=0.95) in
a separate, preliminary study of 40 normal adults and ARM
patients (data not shown). Perhaps more intriguing, the
increase in the amount of rod-mediated dark adaptation
impairment with increasing disease severity as assessed by
the AREDS Severity System for ARM allows the possibility
of using dark adaptation as a clinical outcome measure.
Previously, we evaluated another short-duration protocol
developed for the SST-1 dark adaptometer (LKC Technol-
ogies, Inc) for the detection of early ARM [17]. The SST-1
is a manual dark adaptometer that uses an abbreviated
protocol, typically 20 to 30 minutes. The AdaptDx and the
SST-1 exhibit markedly different response characteristics.
Whereas the AdaptDx shows no difference with aging but
is highly sensitive to ARM, the SST-1 discriminates aging
effects but is insensitive to ARM. An important difference
between the protocols is that the SST-1 measures the
sensitivity recovery of the entire retina, instead of just the
macula or a portion of the macula. Healthy peripheral retina
probably masks the dark adaptation impairment localized to
the macula.
We have developed a short duration protocol that can
sensitively and specifically detect early ARM. Night vision
is the first casualty of ARM. The impaired night vision
encountered in early ARM is a clinically significant
problem similar to acuity impairment encountered in late
ARM. As such, we believe dark adaptation is a suitable
primary endpoint to evaluate efficacy of treatments aimed
at early ARM.
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